Baxter Shares Fall as Insurers Favor Rival’s Blood Products

Baxter International Inc. (BAX), the maker of blood products and intravenous drugs, declined 3.1 percent after an analyst said the company may be hurt by health insurer Aetna Inc.’s decision to favor a rival Grifols (GRF) SA treatment for immune system disorders.

Aetna indicated it plans to consider Barcelona-based Grifols’s Gamunex the “preferred” brand of IVIG, a treatment for immune system disorders, said Matthew Prior, an analyst for Bank of America Merrill Lynch in Melbourne. The decision may limit use of other medications, including Baxter’s Gammagard, Prior wrote in an Oct. 12 note to investors. Baxter, based in Deerfield, Illinois, declined to $54.40 at 4 p.m. New York time.

While details are still unclear, the preferred status for Gamunex is slated to take hold on Jan. 1, Prior said. Hospitals might automatically use Gamunex first and patients may have to pay face higher co-payments if they want an alternative, he said. The decision follows similar moves by Highmark Inc. and Coventry Health Care Inc., smaller health insurers, earlier this year that required patients to use a specific IVIG, he said.

“The ‘preferred’ status could be a softer approach compared to that of Highmark or Coventry that require you to ‘fail first’,” on the specified product before getting access to the others, he wrote.

IVIG, also known as intravenous immunoglobulin, is comprised of antibodies extracted from human blood. It is given to patients with immune system disorders who don’t make enough of their own natural defenses to ward off infections.

Aetna (AET), based in Hartford, Connecticut, is the third-largest U.S. health insurer behind UnitedHealth Group Inc. and WellPoint Inc.

To contact the reporters on this story: Michelle Fay Cortez in Minneapolis at; Drew Armstrong in Washington at

To contact the editor responsible for this story: Reg Gale at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.